Juno Therapeutics, a Seattle-based immunotherapy developer, has filed for an initial public offering with the goal of securing as much as $150 million. The firm plans to use some of the money to advance clinical development of its cancer drug candidates.
Immune Design hopes to raise $60 million in an initial public offering. The Seattle-based drugmaker plans to use the money to further develop its experimental drugs for various cancers including melanoma, breast cancer and sarcoma.
Immune Design, which specializes in developing immune-based cancer treatments, has filed for an initial public offering with the goal of securing $60 million. The Seattle-based biotech firm will use the money to support clinical trials of its cancer drug candidates.
CardioDx, which specializes in noninvasive cardiovascular disease diagnostic tests, has revived its plans to launch an initial public offering although it did not disclose its IPO target. Meanwhile, U.K. device firm Lombard Medical Technologies has moved ahead with its U.S. IPO, obtaining $55 million from the sale of 5 million company shares.
Seattle-based medical device company Northstar Neuroscience, which primarily focuses on the rehabilitation of stroke victims, is seeking up to $85 million in an IPO to fund an advanced clinical trial and develop technology for other applications. No date has been set for the offering.